Companies / Novartis
Novartis
Company- Registered trials
- 1663
- Ongoing
- 121/ 7%
- Completed
- 1213
- Related drugs
- 13
- Related conditions
- 26
Clinical trial landscape
1663 registered studies reference this company or one of its brands. The split below shows how many are ongoing versus completed per phase.
| Phase | Total | Ongoing | Completed | Split |
|---|---|---|---|---|
| Phase 2 | 430 | 47 | 265 | |
| Phase 3 | 383 | 10 | 334 | |
| Phase 4 | 305 | 3 | 245 | |
| Phase 1 | 208 | 16 | 156 | |
| Unknown | 137 | 26 | 89 | |
| Phase 1/2 | 108 | 10 | 70 | |
| Not applicable | 59 | 7 | 31 | |
| Phase 2/3 | 24 | 0 | 17 | |
| Early Phase 1 | 9 | 2 | 6 | |
| All phases | 1663 | 121 | 1213 |
Ongoing Completed Balance withdrawn, terminated, or status unreported.
Study records: ClinicalTrials.gov →
Recent developments
| Novartis Reports Positive Phase III Results for Remibrutinib in Relapsing MS | yahoo.com ↗ | |
| Biocryst HAE Data, BioAge BGE-102 Trial, Alebund Interim Results | biospace.com ↗ | |
| Alnylam Q4 Earnings Beat, Revenue Misses on 85% Growth; Stock Down 4.1% | genengnews.com ↗ | |
| AI in Drug Discovery: Milestones, Limitations and the Push for Clinically Relevant Data | nature.com ↗ | |
| AI Drug Discovery Surges With $2.5B Partnership and $1.7B Takeda-Iambic Deal | news.biobuzz.io ↗ | |
| ChrysCapital-Led Open Offer for Novartis India Sees Minimal Acceptance | m.economictimes.com ↗ | |
| CAM Use Tied to Higher Breast Cancer Death Risk; New Molecule Shows Promise Against Triple-Negative Tumors | jamanetwork.com ↗ | |
| US Tariff Plan Spurs Massive Pharma Investment Wave, Indian Generics on Notice | pharma.economictimes.indiatimes.com ↗ | |
| Novartis Beats Q2 Profit Estimates as New Drugs Offset 50% Entresto Sales Decline | pharmaphorum.com ↗ | |
| FDA Approves Novartis' Fabhalta for IgAN; Vanrafia Data Show Slower Kidney Decline | geneonline.com ↗ |
Headlines link to the original publisher. Sources limited to a reviewed list of journals, regulators, and medical press.